A pair of Baltimore biotech companies are getting $36M to create a new vaccine - Technical.ly Baltimore

Sciences

Aug. 16, 2018 4:38 pm

A pair of Baltimore biotech companies are getting $36M to create a new vaccine

Profectus Biosciences and Emergent Biosolutions are aiming to produce an antidote to the Lassa virus.
Emergent Biosolutions’ Bayview facility.

Emergent Biosolutions' Bayview facility.

(Courtesy photo)

Baltimore biotechs are teaming up in the fight against the Lassa virus.

Profectus Biosciences and Emergent Biosolutions will receive $36 million over five yearesin funding from the Oslo, Norway–based Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine against the rat-borne virus. There is currently no vaccine for Lassa virus, which officials said is a threat to public health in West Africa. CEPI announced the deal Thursday.

Profectus, located off Dundalk Ave., will receive $4.3 million in Phase 1 to develop its Lassa vaccine. We’ve previously covered the company’s involvement in efforts to develop a vaccine for Ebola. Gaithersburg-based Emergent Biosolutions, a publicly-traded biopharmaceutical company with expanding manufacturing operations in the city, will provide technical and manufacturing assistance as part of the deal. In a release, Emergent specifically said its Center for Innovation in Advanced Development and Manufacturing in Bayview was designed to handle an increase in manufacturing during public health emergencies.

Advertisement

In turn, Profectus and Emergent have their own agreement that gives Emergent an exclusive option to license and continue to develop the vaccine.

While 80 percent of people who become infected show no symptoms, Nigeria is facing its largest-ever outbreak of the disease, which has resulted in 121 deaths. Outbreaks have also been reported in Liberia, Nigeria, Sierra Leone and South Sudan, according to CEPI.

The companies seem to have a Baltimore-centered partnership budding, as they also received a $25M grant from CEPI to develop a vaccine for Nipah virus earlier this year.

-30-
CONTRIBUTE TO THE
JOURNALISM FUND

Already a contributor? Sign in here
Connect with companies from the Technical.ly community
New call-to-action

Advertisement

This form of art blends science and technology to tell stories through biological products

Why Baltimore rose to the ‘top of the list’ when this biotech team needed a new HQ

KaloCyte moves to University of Maryland BioPark

SPONSORED

Baltimore

Entrepreneurs, think it’s too early to engage a legal partner? It’s not.

Baltimore, MD

14 West

Qlik Developer

Apply Now

Baltimore, MD

14 West

Senior Qlik Developer

Apply Now

Baltimore, MD

14 West

Lead Qlik Developer

Apply Now

Early Charm Ventures launches Abri Science with $225K in funding

UMB grants licensing option for anticancer drug that uses Anthrax

MICA Game Lab and Shock Trauma are developing VR games for spinal injury patients

SPONSORED

Baltimore

Why two eminent Baltimore higher-ed institutions collaborated to create this unique dual degree program

Baltimore

14 West

Senior Business Analyst

Apply Now

Chantilly, VA

Excivity

Android Software Engineer

Apply Now

Chantilly, VA

Excivity

Software Engineer

Apply Now

Sign-up for daily news updates from Technical.ly Baltimore

Do NOT follow this link or you will be banned from the site!